广告
加载中

一家创新药鼻祖破产:投资者亏麻了

冯雨晨 2026-06-29 11:51
冯雨晨 2026/06/29 11:51

邦小白快读

EN
全文速览

本文核心内容是全球第一代基因编辑技术鼻祖Sangamo破产的全过程,给普通投资者参与创新药投资提供了实操参考。

1. 核心事件梳理:Sangamo1995年成立,独占锌指核酸酶ZFN技术专利30年,曾完成全球首例人体内基因编辑试验,近五年股价累计暴跌99%,2025年申请破产保护,核心技术资产被礼来、安斯泰来底价接盘,高位买入的散户近乎血本无归。

2. 投资实操提醒:投资创新药领域不能只迷信技术先驱光环和概念,要重点核查企业的产品商业化进度、现金流健康度,避开长期没有产品获批上市、过度依赖融资和合作输血的标的,同时要警惕技术迭代带来的行业颠覆性风险。

这一破产案例给创新药品牌商带来了研发战略、商业化布局等多方面的启示。

1. 产品研发层面:Sangamo封闭独占ZFN技术的发展模式,导致技术长期没有大规模应用和突破,而开放共享的CRISPR技术快速迭代反超,提醒品牌商不能打造封闭的技术孤岛,要保持开放研发,跟进新技术迭代,避免抱残守缺。

2. 商业化布局层面:当下行业市场不再为概念买单,更看重成熟临床数据和商业化效率,企业需要平衡研发进度和商业化节奏,提前规划商业化路径,还要提前评估产品上市后的市场接受度,避免因商业化前景不被看好丢失合作。

3. 风险管控层面:企业要提前储备现金流,避免过度依赖头部企业合作收入,防范合作终止带来的致命冲击。

本文梳理了当前创新药行业的最新趋势,给创新药领域的初创经营者提供了风险提示和机会参考。

1. 行业趋势变化:当前全球创新药Biotech正经历一轮冷静出清,行业逻辑发生转变,过去靠平台、愿景、概念就能支撑估值,现在市场更看重成熟临床数据、商业化效率以及企业能否独立走完临床流程。

2. 核心风险提示:要警惕两类风险,一是技术迭代风险,封闭独占技术的模式很容易被开放的新技术颠覆;二是现金流风险,过度依赖融资和巨头合作收入,一旦合作终止就很容易陷入现金流断裂绝境。

3. 机会提示:当前中国创新药已经进入利润兑现期,中国创新药资产成为全球研发的核心力量,2026年一季度对外授权总额已经接近2025年全年的一半,深耕有临床验证价值赛道的初创企业有更大机会脱颖而出。

本文给医药生产研发类工厂带来了创新药行业的发展启示和商业机会梳理。

1. 产品需求变化:当前创新药行业进入整合期,头部药企纷纷收购破产Biotech的核心技术管线,相关前沿疗法的生产研发配套需求会逐步释放,工厂可以提前布局对应技术路线的生产能力,抢抓订单。

2. 发展方向启示:创新药领域技术迭代速度快,工厂不能只绑定单一落后技术路线配套生产,要跟进开放型新技术的研发生产需求,拓展多管线服务能力,提升自身抗风险能力。

3. 商业机会提示:当前中国创新药出海速度加快,对外授权规模快速增长,相关工厂可以抓住国产创新药出海的趋势,拓展海外配套生产业务,同时可以推进自身研发生产的数字化升级,匹配创新药企业的高效研发需求。

本文给创新药行业服务商梳理了当前行业发展趋势、客户核心痛点以及新的业务方向。

1. 行业发展趋势:当前全球创新药行业进入分化洗牌和整合阶段,大量中小型Biotech出清,头部药企加速收购优质技术资产,行业格局变化带来了新的服务需求。

2. 客户核心痛点:初创Biotech普遍存在现金流储备不足、商业化能力缺失、抗风险能力弱、技术路线容易被颠覆等痛点,多数企业难以独立走完漫长的临床研发流程,而头部药企有整合优质低价技术资产的需求,存在信息不对称问题。

3. 解决方案布局方向:服务商可以针对初创企业推出临床进度管控、现金流规划、融资对接等服务,还可以搭建技术资产交易对接平台,满足头部药企收购破产企业核心资产的对接需求,挖掘新的业务增长点。

本文给创新药领域的投融资、产业平台商梳理了当前行业需求,以及运营和招商方向。

1. 平台新需求:当前创新药进入出清整合阶段,大量破产Biotech有核心技术资产转让、拍卖的需求,头部药企有低价收购优质技术管线的需求,平台可以新增技术资产交易对接板块,匹配买卖双方的需求,打造新的业务增长点。

2. 运营风险规避:平台在推广创新药项目时,不能只炒作技术光环和概念,要主动向投资者提示项目风险,要求项目方披露临床进度、现金流、商业化规划等核心信息,规避后续的投资纠纷和舆情风险。

3. 招商布局方向:当前中国创新药已经进入利润兑现期,出海授权规模快速增长,平台可以重点引入拥有成熟临床数据、具备商业化潜力的国产创新药项目,契合行业发展新趋势,提升平台吸引力。

本文提供了Biotech企业发展的经典失败案例,也梳理了当前全球及中国创新药产业的最新动向,对产业研究有较高参考价值。

1. 产业新动向:当前全球创新药产业正在经历一轮冷静出清,高成本长周期的前沿Biotech洗牌加速,行业投资逻辑从看重概念想象力转向看重经临床验证的商业化能力;中国创新药已经进入利润兑现期,对外授权规模快速增长,中国资产已经成为全球创新药研发不可或缺的核心力量。

2. 产业新问题:暴露了封闭独占式研发模式的弊端,封闭发展缺少行业碰撞,容易导致技术停滞,最终被开放共享的新技术反超;同时也暴露了依赖融资和合作输血、没有自主造血能力的Biotech抗风险能力极弱,很容易遭遇黑天鹅倒闭。

3. 研究启示:该案例为研究创新药企业的研发战略、商业化路径、风险管控提供了教科书级样本,对研究创新药产业发展规律、探索适合本土的创新药商业模式有重要参考意义。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

This article details the entire bankruptcy process of Sangamo Therapeutics, the pioneer of the world's first-generation gene editing technology, and provides practical guidance for retail investors investing in innovative drugs.

1. Core event timeline: Founded in 1995, Sangamo held exclusive patents on zinc-finger nuclease (ZFN) technology for 30 years and completed the world's first in vivo gene editing trial. Its stock plummeted 99% over the past five years before it filed for bankruptcy protection in 2025. Its core technology assets were acquired at fire-sale prices by Eli Lilly and Astellas, leaving retail investors who bought at peak prices with nearly total losses.

2. Practical investment takeaways: Investing in innovative drugs should not rely solely on the reputation of technical pioneers or hype around concepts. Investors must focus on verifying a company's product commercialization progress and cash flow health, and avoid targets that have no approved products for long periods and rely excessively on financing and partnership funding. They should also remain alert to the disruptive industry risk brought by technological iteration.

This bankruptcy case offers multiple insights on R&D strategy and commercialization planning for innovative drug brand owners.

1. Product R&D: Sangamo's closed, exclusive development model for ZFN left the technology without large-scale application or breakthroughs for years, while the open, shared CRISPR technology rapidly iterated and surpassed it. This reminds brand owners not to build closed technical silos; instead, they should maintain open R&D practices, keep up with new technological iterations, and avoid clinging to outdated approaches.

2. Commercialization planning: The current industry no longer values empty concepts, but prioritizes solid clinical data and commercialization efficiency. Companies must balance R&D progress with commercialization rhythm, plan commercialization paths early, and assess market acceptance of products before launch to avoid losing partnerships due to unconvincing commercial prospects.

3. Risk management: Companies must build up sufficient cash reserves in advance, avoid over-reliance on partnership revenue from large pharmaceutical firms, and guard against the fatal impact of terminated partnerships.

This article sorts out the latest trends in the innovative drug industry and provides risk alerts and opportunity references for startup operators in the sector.

1. Changing industry trends: The global innovative drug biotech sector is currently undergoing a cooling-off and consolidation period, and industry valuation logic has shifted. Whereas valuations were once supported by platforms, vision and concepts alone, the market now values mature clinical data, commercialization efficiency, and a company's ability to complete clinical development independently.

2. Core risk alerts: Two major risks require attention. First, the risk of technological iteration: closed, exclusive technology models are easily disrupted by open new technologies. Second, cash flow risk: over-reliance on financing and revenue from big pharma partnerships can quickly lead to fatal cash flow crunches if a partnership is terminated.

3. Opportunity outlook: China's innovative drug sector has now entered a phase of profit realization, and Chinese innovative drug assets have become a core force in global R&D. Total outbound licensing volume in Q1 2026 already reached nearly half of the full-year 2025 total, and startups focused on clinically validated tracks have greater odds of standing out.

This article outlines development insights and business opportunities for pharmaceutical R&D and manufacturing facilities in the innovative drug industry.

1. Changing product demand: The innovative drug industry is currently in a consolidation phase, with leading pharmaceutical companies actively acquiring core technology pipelines from bankrupt biotechs. Demand for R&D and manufacturing support for cutting-edge therapies will gradually increase. Facilities can build up production capacity aligned with emerging technical routes in advance to capture new orders.

2. Development direction insights: Technological iteration in innovative drugs is fast-paced, so facilities should not tie themselves exclusively to outdated single technical routes. They should keep up with R&D and manufacturing demand for open new technologies, expand multi-pipeline service capabilities, and improve their own risk resistance.

3. Business opportunity outlook: Chinese innovative drugs are accelerating their global expansion, and outbound licensing scale is growing rapidly. Domestic facilities can leverage this trend to expand overseas contract manufacturing business, while advancing digital upgrades of their own R&D and manufacturing operations to meet the efficient R&D demands of innovative drug companies.

This article sorts out current industry development trends, core client pain points and new business directions for service providers in the innovative drug sector.

1. Industry development trends: The global innovative drug industry is currently in a phase of differentiation, restructuring and consolidation. A large number of small and medium-sized biotechs are being shaken out, while leading pharmaceutical companies are accelerating acquisitions of high-quality technical assets. This changing industry landscape has created new service demand.

2. Core client pain points: Startup biotechs generally suffer from insufficient cash reserves, lack of commercialization capabilities, weak risk resistance, and vulnerability to disruption of their technical routes, with most unable to independently complete the long clinical R&D process. Meanwhile, leading pharmaceutical companies face information asymmetry when seeking to acquire high-quality technical assets at low valuations.

3. Solution and business development directions: Service providers can offer startup-focused services including clinical progress management, cash flow planning, and financing matchmaking. They can also build technical asset trading and matching platforms to meet leading pharma's demand for deal sourcing for core assets from bankrupt companies, unlocking new sources of growth.

This article sorts out current industry demand, as well as operation and investment promotion directions for investment and industrial platforms in the innovative drug sector.

1. New platform demand: As the innovative drug sector enters a phase of shakeout and consolidation, a large number of bankrupt biotechs need to transfer or auction their core technical assets, while leading pharmaceutical companies want to acquire high-quality pipelines at low prices. Platforms can add a technical asset trading and matching segment to connect buyers and sellers and build a new growth driver.

2. Operational risk mitigation: When promoting innovative drug projects, platforms should not just hype technical reputation and concepts. They must proactively disclose project risks to investors, and require project sponsors to disclose core information including clinical progress, cash flow status and commercialization plans to avoid future investment disputes and reputational risks.

3. Investment promotion strategy: China's innovative drug sector has entered a profit realization phase with rapidly growing outbound licensing scale. Platforms can prioritize onboarding domestic innovative drug projects with mature clinical data and commercial potential to align with new industry trends and boost platform attractiveness.

This article provides a classic failure case of biotech enterprise development and sorts out the latest developments in the global and Chinese innovative drug industries, offering high reference value for industrial research.

1. New industry developments: The global innovative drug industry is currently undergoing a cooling consolidation, with accelerated shakeout in high-cost, long-cycle frontier biotech segments. Industry investment logic has shifted from prioritizing conceptual potential to focusing on clinically validated commercial capabilities. China's innovative drug sector has entered a phase of profit realization with rapidly expanding outbound licensing, and Chinese assets have become an indispensable core force for global innovative drug R&D.

2. New industry issues: The case exposes the drawbacks of the closed, exclusive R&D model: closed development lacks industry interaction, easily leads to technological stagnation, and ultimately ends up being overtaken by open, shared new technologies. It also shows that biotechs that rely on financing and partnership funding and lack independent profitability have extremely weak risk resistance, and are highly vulnerable to collapse from unexpected black swan events.

3. Research implications: This case serves as a textbook example for research on innovative drug enterprise R&D strategy, commercialization paths, and risk management. It has important reference value for studying the development law of the innovative drug industry and exploring locally suited innovative drug business models.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

唏嘘。

作者/冯雨晨

报道/投资界PEdaily

“如此生活30年,直到大厦崩塌。”

这是一位创新药孤勇者的落寞:诞生于1995年的Sangamo Therapeutics,独占第一代基因编辑技术专利30年,一度被视为基因编辑领域的鼻祖。

然而近五年间,Sangamo股价累计暴跌99%。就在本周,Sangamo正式申请破产保护并计划出售几乎全部资产,同时开启大裁员。

在破产之前,机构投资人悉数离场。只是,散户股民损失不小——尤其是2020年高点那些在15元至19美元买入的股民,近乎血本无归。打开某股票社区,该公司专区过往有着500多位活跃股民,如今只有零星回复。

一个教科书级Biotech崩盘案例浮现。

漫漫30年

昔日行业鼻祖走入绝境

Sangamo曾引领着行业的想象。

一切开端于1995年。创始人Edward Lanphier以75万美元创办了Sangamo,押注人类历史上第一种基因编辑技术锌指核酸酶(ZFN)——用工程化蛋白质精准找到人类基因组上的特定序列,然后像剪刀一样剪开DNA双链,进行编辑或修复。

从一开始,Edward Lanphier就决定要将Sangamo打造成一个外人无法从中分一杯羹的技术孤岛,也就是把ZFN的设计、优化到临床应用这一整套技术体系专利产权尽数收入囊中。

这相当野心勃勃,此后ZFN技术开发牢牢被Sangamo独家锁定,再也没有其它机构能够从事ZFN的研发。

2017年,Sangamo成功造就了人类历史上第一次在人体内进行基因编辑尝试的时刻。那一年,44岁的亨特综合征患者布莱恩·马德克斯接受了Sangamo的SB-913疗法,医生将携带锌指核酸酶的病毒载体直接注射进他的肝脏,试图在他的肝细胞里修复一个缺陷基因。

毫无疑问,Sangamo是人类基因编辑产业的技术先驱。但有人的地方就有江湖,有江湖的地方就有博弈。

2012年前后,第三代基因编辑技术CRISPR以摧枯拉朽之势席卷而来。与ZFN的研发周期长、成本高、技术门槛高不同,CRISPR技术是用RNA来识别DNA序列,合成一段RNA只需要几天时间,成本只要几十美元。并且,ZFN技术是被Sangamo独占主导,但CRISPR却一经问世后便迅速开枝散叶,在不同细分赛道百花齐放。

某种程度上,Sangamo选择关上门独享ZFN技术所有可能的同时,也是在孤军奋战。

CRISPR技术在激烈竞争和智慧碰撞中不断迸发新的细分路径,临床试验越来越多,出现了许多不错的治疗效果。而被Sangamo独享的ZFN问世至今一直没获得大规模的应用和突破性进展,且30年来,Sangamo始终没有一款疗法获批上市。

“他们手里握着一把最精密的手术刀,但世界已经等不及了。”有投资者私下评价。

黯然宣布破产

礼来捡漏

坠落不是一夜间发生。

成立近30年,Sangamo虽然未有产品上市和盈利,但相当长一段时间并未为钱发愁过。

2012年,Sangamo登陆纳斯达克,然后又进行了三轮融资:2013年9月,融资742万美金,帮助公司加速基因治疗发展;2018年2月,获得美国国家卫生研究院1100万美元拨款;2018年4月,获得加利福尼亚再生医学研究所800万美元拨款。

募资之外,Sangamo也和辉瑞、赛诺菲、吉利德等制药巨头们合作获得收入。

可以说,Sangamo充分享受着专利堡垒的果实和光环,以至于后来的坍塌颇有种“命运所有的馈赠,都在暗中标好了价格”意味。

作为一家Biotech,Sangamo连续多年来没有造血能力不是最致命的,但当手中王牌ZFN技术开始遇到新技术的挑战,商业化依然迟迟不见踪影,也未能释放出真正造福人类的潜力,市场不由得打上了大大的问号。

2022年1月,赛诺菲将镰状细胞病候选药物BIVV-003的完全控制权归还给Sangamo,2023年2月,Sangamo索性宣布放弃开发BIVV-003;2023年3月,诺华和渤健也相继终止和Sangamo的合作协议,为此,Sangamo不得不裁员自保。

致命一击,来自辉瑞。

2024年12月,辉瑞宣布终止与Sangamo在A型血友病基因疗法上的合作。终止理由并非是疗效不好,毕竟该疗法的三期临床试验已达到主要终点正准备提交上市申请,而是因为当时辉瑞看到一个前车之鉴:拜玛林制药公司的血友病A基因疗法Roctavian虽然2023年获批,却商业化惨淡、鲜有患者使用。

这让本就现金流紧张的Sangamo直接陷入僵局。一个季度后的2025年3月底,Sangamo账上现金仅剩1800万美元,股价徘徊在0.5美元/股附近,至今每股已不足0.2美元,流动性趋近于零。

如今走到破产,Sangamo的姿态已经不是收缩,而是拆分。

6月23日,Sangamo启动破产程序,Sangamo按照“假马竞标人”规则拍卖,礼来与安斯泰来作为保底买家入场,他们已为Sangamo的核心资产约定了最低收购价,若没有其他药企报出更高价格,两家巨头将按约定价格接盘。其中,礼来拟买下的是Sangamo的衣壳递送平台、锌指平台、模块化整合酶(MINT)平台及朊病毒疾病项目ST-506,安斯泰来则瞄准其用于治疗法布里病的项目ST-920。

30年几积淀下来的技术遗产依然是稀缺资源,只是Sangamo不再是主角了。

医药投资人继续熬

毋庸置疑,整个创新药产业在向上崛起。

但分化和洗牌也在继续。Sangamo的离场不是孤例,近年来,高成本、长周期、强监管的前沿Biotech正在经历一轮更冷静的出清:

如2024年年初,专注于 大分子创新药物研发的博际生物提交破产清算申请,随后联拓生物(LIAN.US)宣布开始逐步缩减其业务,包括出售剩余资产、裁员、从纳斯达克退市和逐步停止其临床试验;

2025年2月,美国做可编程表观基因组mRNA药物的公司Omega Therapeutics在特拉华州申请第11章破产保护,而它在13个月前还与Novo Nordisk达成过潜在总额5.32亿美元的合作;

2026年,Nido Biosciences是首家倒下的Biotech,该公司因一款针对罕见神经系统疾病的小分子药物2期临床试验数据不佳,早早宣布停止运营;随后,聚焦免疫调节型抗癌疫苗研发的丹麦生物科技公司IO Biotech提交破产申请,正式宣布停止所有运营。

如果说平台、愿景和概念过去可以支撑一家公司的估值,现在,市场更加想看到的是成熟临床数据、商业化效率以及一家小公司能否独立走完漫长的临床旅程。在这个层面上,行业洗牌真正筛掉的往往不是想象力,而是没有被验证的想象力。

个体境遇之外,眼下中国创新药行业亦处在一种阶段性的失意中。

“创新药与AI两大领域可以说是冰火两重天”。

不久前的2026投资界SuperLink大会的生物医药专场,一位从业十几年的医疗投资人感叹:现在是一个前所未有的强共识时代,所有机构都紧盯几个有限赛道,而生物医药在其中处于比上不足、比下有余的位置。

不难看到,创新药指数已跌回2025年中旬即上一轮行情启动前的位置。此时此刻,大家都在等待行业的春天来临。

所幸,中国创新药企业已经开始进入利润兑现期。与此同时,中国资产正在成为全球创新药研发中不可或缺的核心力量——2026年第一季度,中国创新药对外授权总额就已突破600亿美元,这个数字已经接近2025年全年规模的一半。

医疗行业从来都是长坡厚雪。大部分人依然相信,当真正属于生物医药的春天再到来时,花自然会开。

只是眼前,依旧煎熬。

注:文/冯雨晨,文章来源:投资界(公众号ID:pedaily2012),本文为作者独立观点,不代表亿邦动力立场。

文章来源:投资界

广告
微信
朋友圈

这么好看,分享一下?

朋友圈 分享

APP内打开

赞 +1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0